miR-28-based combination therapy impairs aggressive B cell lymphoma growth by rewiring DNA replication

miR-28-based combination therapy impairs aggressive B cell lymphoma growth by rewiring DNA replication

Abstract Diffuse large B cell lymphoma (DLBCL) is the most common aggressive B cell lymphoma and accounts for nearly 40% of cases of B cell non-Hodgkin lymphoma. DLBCL is generally treated with R-CHOP chemotherapy, but many patients do not respond or relapse after treatment. Here, we analyzed the th...

Full description

Bibliographic Details
Main Authors: Teresa Fuertes, Emigdio Álvarez-Corrales, Carmen Gómez-Escolar, Patricia Ubieto-Capella, Álvaro Serrano-Navarro, Antonio de Molina, Juan Méndez, Almudena R. Ramiro, Virginia G. de Yébenes
Format: Article
Language:English
Published: Nature Publishing Group 2023-10-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-023-06178-0

Internet

https://doi.org/10.1038/s41419-023-06178-0

Similar Items